Lunai Bioworks, Inc., formerly Renovaro Inc., is focused on AI-powered biodefense, drug discovery and advanced diagnostics. The Company is engaged in harnessing advanced computational biology and AI/machine learning to accelerate drug discovery, diagnostics and strengthen biosecurity capabilities. From high-resolution phenotyping to predictive disease modeling, the Company is pioneering a new era of precision diagnostics-where early detection, patient stratification, and therapeutic targeting converge into a single, adaptive platform. These are designed to transform clinical decision-making, reduce time-to-treatment, and unlock previously inaccessible insights from biological data. Its proprietary platforms in translational analytics, in vivo modeling, and machine vision-accelerating biomarker discovery and therapeutic development in precision neurology and infectious disease.
公司代碼RENB
公司名稱Renovaro Inc
上市日期Nov 18, 2014
CEOWeinstein (David)
員工數量- -
證券類型Ordinary Share
年結日Nov 18
公司地址2080 Century Park East, Suite 906
城市LOS ANGELES
上市交易所NASDAQ Capital Market Consolidated
國家United States of America
郵編90067
電話14539179840
網址
公司代碼RENB
上市日期Nov 18, 2014
CEOWeinstein (David)